Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK

Ou, 2020, Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV, Nat. Commun., 11, 1620, 10.1038/s41467-020-15562-9 Grasselli, 2020, Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA, 323, 1574, 10.1001/jama.2020.5394 Guo, 2020, Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19), JAMA Cardiology, 5, 811, 10.1001/jamacardio.2020.1017 Petrilli, 2020, Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study, BMJ, 369, m1966, 10.1136/bmj.m1966 Hu Greenhalgh, 2020, Covid-19: a remote assessment in primary care, BMJ, 368 368, m1182, 10.1136/bmj.m1182 Herbert, 2018, Regulation of low-density lipoprotein cholesterol by intestinal inflammation and the acute phase response, Cardiovasc. Res., 114, 226, 10.1093/cvr/cvx237 Feng, 2019, Association between low-density lipoprotein cholesterol levels and risk for sepsis among patients admitted to the hospital with infection, JAMA Netw Open, 2, 10.1001/jamanetworkopen.2018.7223 Golucci, 2018, Lipid profile associated with the systemic inflammatory response syndrome and sepsis in critically ill patients, Nutrition, 55–56, 7, 10.1016/j.nut.2018.04.007 Halperin, 2016, Further evolution of the ACC/AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology/American heart association task force on clinical practice guidelines, Circulation, 133, 1426, 10.1161/CIR.0000000000000312 Banach, 2020, Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic, Pharmacol. Res., 158, 104891, 10.1016/j.phrs.2020.104891 Vuorio, 2020, Familial hypercholesterolemia and COVID-19: triggering of increased sustained cardiovascular risk, J. Intern. Med., 287, 746, 10.1111/joim.13070 Khera, 2020, Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: a scientific statement from the American Society for Preventive Cardiology, American Journal of Preventive Cardiology, 1, 100009, 10.1016/j.ajpc.2020.100009 Fan, 2020, Clinical features of COVID-19-related liver damage, Clin. Gastroenterol. Hepatol., 18, 1561, 10.1016/j.cgh.2020.04.002 Feng, 2020, COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies, Journal of Clinical and Translational Hepatology, 8, 18, 10.14218/JCTH.2020.00018 Stone, 2013, ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J. Am. Coll. Cardiol., 63, 2889, 10.1016/j.jacc.2013.11.002 Soran, 2015, Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment, Eur. Heart J., 36, 2975 Schönbeck, 2004, Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?, Circulation, 109, II, 10.1161/01.CIR.0000129505.34151.23 Almog, 2003, Statins, inflammation, and sepsis: hypothesis, Chest, 124, 740, 10.1378/chest.124.2.740 Zeiser, 2018, Immune modulatory effects of statins, Immunology, 154, 69, 10.1111/imm.12902 Koh, 2000, Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability, Cardiovasc. Res., 47, 648, 10.1016/S0008-6363(00)00146-2 South, 2020, COVID-19, ACE2 and the cardiovascular consequences, Am. J. Physiol. Heart Circ. Physiol., 318, H1084, 10.1152/ajpheart.00217.2020 Patel, 2020, COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence?, J. Am. Med. Assoc., 323, 1769 Vaduganathan, 2020, Renin–angiotensin–aldosterone system inhibitors in patients with covid-19, N. Engl. J. Med., 382, 1653, 10.1056/NEJMsr2005760 Bean, 2020, Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust, Eur. J. Heart Fail., 22, 967, 10.1002/ejhf.1924 Shin, 2017, The effect of fluvastatin on cardiac fibrosis and angiotensin-converting enzyme-2 expression in glucose-controlled diabetic rat hearts, Heart Ves., 32, 618, 10.1007/s00380-016-0936-5 Tikoo, 2015, Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications, Biochem. Pharmacol., 93, 343, 10.1016/j.bcp.2014.11.013 Aguilar, 2011, [Atorvastatin induced increase in homologous angiotensin I converting enzyme (ACE2) mRNA is associated to decreased fibrosis and decreased left ventricular hypertrophy in a rat model of diabetic cardiomyopathy], Rev. Peru. Med. Exp. Salud Pública, 28, 264, 10.1590/S1726-46342011000200013 Li, 2013, Effects of rosuvastatin on expression of angiotensin-converting enzyme 2 after vascular balloon injury in rats, J Geriatr Cardiol, 10, 151 de Simone, 2020 Mancia, 2020, Renin–angiotensin–aldosterone system blockers and the risk of Covid-19, N. Engl. J. Med., 2431, 10.1056/NEJMoa2006923 Reynolds, 2020, Renin–angiotensin–aldosterone system inhibitors and risk of Covid-19, N. Engl. J. Med., 382, 2441, 10.1056/NEJMoa2008975 Meng, 2020, Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension, Emerg. Microb. Infect., 9, 757, 10.1080/22221751.2020.1746200 Reiner, 2020, Statins and the COVID-19 main protease: in silico evidence on direct interaction, Arch. Med. Sci., 16, 490, 10.5114/aoms.2020.94655 Varga, 2020, Endothelial cell infection and endotheliitis in COVID-19, Lancet, 395, 1417, 10.1016/S0140-6736(20)30937-5 Xu, 2020, Pathological findings of COVID-19 associated with acute respiratory distress syndrome, The Lancet respiratory medicine, 8, 420, 10.1016/S2213-2600(20)30076-X Ñamendys-Silva, 2020, ECMO for ARDS due to COVID-19, Heart Lung, 49, 348, 10.1016/j.hrtlng.2020.03.012 Lewis, 2019, Pharmacological agents for adults with acute respiratory distress syndrome, Cochrane Database Syst. Rev., 7, CD004477 Grudzinska, 2017, Statin therapy in patients with community-acquired pneumonia, Clin. Med., 17, 403, 10.7861/clinmedicine.17-5-403 Yende, 2011, Understanding the potential role of statins in pneumonia and sepsis, Crit. Care Med., 39, 1871, 10.1097/CCM.0b013e31821b8290 Chopra, 2012, Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-analysis, Am. J. Med., 125, 1111, 10.1016/j.amjmed.2012.04.011 Kwong, 2009, Influenza morbidity and mortality in elderly patients receiving statins: a cohort study, PloS One, 4, 10.1371/journal.pone.0008087 Schlienger, 2007, Statins and the risk of pneumonia: a population-based, nested case-control study, Pharmacotherapy, 27, 325, 10.1592/phco.27.3.325 Fedson, 2013, Treating influenza with statins and other immunomodulatory agents, Antivir. Res., 99, 417, 10.1016/j.antiviral.2013.06.018 Dublin, 2009, Statin use and risk of community acquired pneumonia in older people: population based case-control study, Br. Med. J., 338, b2137, 10.1136/bmj.b2137 Yuan, 2015, Statins may decrease the fatality rate of Middle East respiratory syndrome infection, mBio, 6, 10.1128/mBio.01120-15 Hackam, 2006, Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis, Lancet, 367, 413, 10.1016/S0140-6736(06)68041-0 Halcox, 2004, Beyond the laboratory: clinical implications for statin pleiotropy, Circulation, 109, II, 10.1161/01.CIR.0000129500.29229.92 Soran, 2017, Evidence for more intensive cholesterol lowering, Curr. Opin. Lipidol., 28, 291, 10.1097/MOL.0000000000000433 Lai, 2016, Statin treatment is associated with a decreased risk of active tuberculosis: an analysis of a nationally representative cohort, Thorax, 71, 646, 10.1136/thoraxjnl-2015-207052 Soran, 2018, Acquired low cholesterol: diagnosis and relevance to safety of low LDL therapeutic targets, Curr. Opin. Lipidol., 29, 318, 10.1097/MOL.0000000000000526 Banach, 2018, The role of nutraceuticals in statin intolerant patients, J. Am. Coll. Cardiol., 72, 96, 10.1016/j.jacc.2018.04.040 Dujovne, 2017, Red yeast rice preparations: are they suitable substitutions for statins?, Am. J. Med., 130, 1148, 10.1016/j.amjmed.2017.05.013 Schofield, 2013, High-density lipoprotein cholesterol raising: does it matter?, Curr. Opin. Cardiol., 28, 464, 10.1097/HCO.0b013e328362210d Machowicz, 2017, Similar but not the same: differential diagnosis of HLH and sepsis, Crit. Rev. Oncol. Hematol., 114, 1, 10.1016/j.critrevonc.2017.03.023 Mehta, 2020, COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet, 395, 1033, 10.1016/S0140-6736(20)30628-0 Budd, 2007, Increased survival after gemfibrozil treatment of severe mouse influenza, AAC (Antimicrob. Agents Chemother.), 51, 2965, 10.1128/AAC.00219-07 Xu, 2015, Combinations of oseltamivir and fibrates prolong the mean survival time of mice infected with the lethal H7N9 influenza virus, J. Gen. Virol., 96, 46, 10.1099/vir.0.069799-0 Hendrickson, 1982, Clofibrate and eosinophilic pneumonia, J. Am. Med. Assoc., 247, 10.1001/jama.1982.03320470030021 Gaist, 2001, Lipid-lowering drugs and risk of myopathy: a population-based follow-up study, Epidemiology, 12, 565, 10.1097/00001648-200109000-00017 Pierce, 1990, Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy, J. Am. Med. Assoc., 264, 71, 10.1001/jama.1990.03450010075034 Davidson, 2007, Safety considerations with fibrate therapy, Am. J. Cardiol., 99, 3c, 10.1016/j.amjcard.2006.11.016 Hottelart, 2002, Fenofibrate increases creatininemia by increasing metabolic production of creatinine, Nephron, 92, 536, 10.1159/000064083 Leiss, 1985, Effect of gemfibrozil on biliary lipid metabolism in normolipemic subjects, Metabolism, 34, 74, 10.1016/0026-0495(85)90064-2 Ascah, 1998, Interaction between fenofibrate and warfarin, Ann. Pharmacother., 32, 765, 10.1345/aph.17310 Piepoli, 2016, Eur. Heart J., 37, 2315, 10.1093/eurheartj/ehw106 Okopień, 2018, Benefits and risks of the treatment with fibrates––a comprehensive summary, Expet Rev. Clin. Pharmacol., 11, 1099, 10.1080/17512433.2018.1537780 Phan, 2012, Ezetimibe therapy: mechanism of action and clinical update, Vasc. Health Risk Manag., 8, 415 Savarese, 2015, Safety and efficacy of ezetimibe: a meta-analysis, Int. J. Cardiol., 201, 247, 10.1016/j.ijcard.2015.08.103 Cannon, 2015, Ezetimibe added to statin therapy after acute coronary syndromes, N. Engl. J. Med., 372, 2387, 10.1056/NEJMoa1410489 Hess, 2018, PCSK9 inhibitors: mechanisms of action, metabolic effects, and clinical outcomes, Annu. Rev. Med., 69, 133, 10.1146/annurev-med-042716-091351 Giugliano, 2017, Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial, Lancet, 390, 1962, 10.1016/S0140-6736(17)32290-0 Sabatine, 2017, Evolocumab and clinical outcomes in patients with cardiovascular disease, N. Engl. J. Med., 376, 1713, 10.1056/NEJMoa1615664 Ridker, 2017, Cardiovascular efficacy and safety of bococizumab in high-risk patients, N. Engl. J. Med., 376, 1527, 10.1056/NEJMoa1701488 Iqbal, 2019, Efficacy and safety of PCSK9 monoclonal antibodies, Expet Opin. Drug Saf., 1 Paciullo, 2017, PCSK9 at the crossroad of cholesterol metabolism and immune function during infections, J. Cell. Physiol., 232, 2330, 10.1002/jcp.25767 Khademi, 2018, PCSK9 and infection: a potentially useful or dangerous association?, J. Cell. Physiol., 233, 2920, 10.1002/jcp.26040 Momtazi, 2017, PCSK9 inhibitors in sepsis: a new potential indication?, Expet Opin. Invest. Drugs, 26, 137, 10.1080/13543784.2017.1272570 Ruscica, 2019, PCSK9 inhibition and inflammation: a narrative review, Atherosclerosis, 288, 146, 10.1016/j.atherosclerosis.2019.07.015 Hansel, 2010, The safety and side effects of monoclonal antibodies, Nat. Rev. Drug Discov., 9, 325, 10.1038/nrd3003 Kasichayanula, 2018, Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor, Clin. Pharmacokinet., 57, 769, 10.1007/s40262-017-0620-7 Harris, 1997, n-3 fatty acids and serum lipoproteins: human studies, Am. J. Clin. Nutr., 65, 1645S, 10.1093/ajcn/65.5.1645S Leslie, 2015, A review of the effect of omega-3 polyunsaturated fatty acids on blood triacylglycerol levels in normolipidemic and borderline hyperlipidemic individuals, Lipids Health Dis., 14, 53, 10.1186/s12944-015-0049-7 Brinton, 2013, Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study, Cardiovasc. Diabetol., 12, 100, 10.1186/1475-2840-12-100 Mozaffarian, 2011, Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events, J. Am. Coll. Cardiol., 58, 2047, 10.1016/j.jacc.2011.06.063 Miller, 2014, Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials, Am. J. Hypertens., 27, 885, 10.1093/ajh/hpu024 Von Schacky, 1985, Long-term effects of dietary marine omega-3 fatty acids upon plasma and cellular lipids, platelet function, and eicosanoid formation in humans, J. Clin. Invest., 76, 1626, 10.1172/JCI112147 Li, 2014, Effect of marine-derived n-3 polyunsaturated fatty acids on C-reactive protein, interleukin 6 and tumor necrosis factor α: a meta-analysis, PloS One, 9 Thies, 2003, Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial, Lancet, 361, 477, 10.1016/S0140-6736(03)12468-3 Konishi, 2019, Eicosapentaenoic acid therapy is associated with decreased coronary plaque instability assessed using optical frequency domain imaging, Clin. Cardiol., 42, 618, 10.1002/clc.23185 Marik, 2009, Omega‐3 dietary supplements and the risk of cardiovascular events: a systematic review, Clin. Cardiol.: An International Indexed and Peer‐Reviewed Journal for Advances in the Treatment of Cardiovascular Disease, 32, 365, 10.1002/clc.20604 Kwak, 2012, Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials, Arch. Intern. Med., 172, 686, 10.1001/archinternmed.2012.262 Del Gobbo, 2016, Cohorts for heart and aging research in genomic epidemiology (CHARGE) fatty acids and outcomes research consortium (FORCe). ω-3 polyunsaturated fatty acid biomarkers and coronary heart disease: pooling project of 19 cohort studies, JAMA Intern Med, 176, 1155, 10.1001/jamainternmed.2016.2925 Chowdhury, 2014, Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis, Ann. Intern. Med., 160, 398, 10.7326/M13-1788 Bhatt, 2019, Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia, N. Engl. J. Med., 380, 11, 10.1056/NEJMoa1812792 Harris, 2007, Expert opinion: omega-3 fatty acids and bleeding-cause for concern?, Am. J. Cardiol., 99, 44c, 10.1016/j.amjcard.2006.11.021 Jeansen, 2018, Fish oil LC-PUFAs do not affect blood coagulation parameters and bleeding manifestations: analysis of 8 clinical studies with selected patient groups on omega-3-enriched medical nutrition, Clin. Nutr., 37, 948, 10.1016/j.clnu.2017.03.027 Group, 2018, Effects of n−3 fatty acid supplements in diabetes mellitus, N. Engl. J. Med., 379, 1540, 10.1056/NEJMoa1804989 Soran, 2018, Hypercholesterolaemia - practical information for non-specialists, Arch. Med. Sci., 14, 1, 10.5114/aoms.2018.72238 Feingold, 2000, Cholesterol lowering drugs Kamanna, 2008, Mechanism of action of niacin, Am. J. Cardiol., 101, S20, 10.1016/j.amjcard.2008.02.029 Yadav, 2015, Effect of extended‐release niacin on high‐density lipoprotein (HDL) functionality, lipoprotein metabolism, and mediators of vascular inflammation in statin‐treated patients, Journal of the American Heart Association, 4, 10.1161/JAHA.114.001508 Mullangi, 2011, Niacin and its metabolites: role of LC-MS/MS bioanalytical methods and update on clinical pharmacology. An overview, Biomed. Chromatogr., 25, 218, 10.1002/bmc.1522 Yadav, 2012, Safety and tolerability of extended-release niacin with laropiprant, Expet Opin. Drug Saf., 11, 151, 10.1517/14740338.2011.638281 Schandelmaier, 2017, Niacin for primary and secondary prevention of cardiovascular events, Cochrane Database Syst. Rev., 6, Cd009744 Jackevicius, 2013, Use of niacin in the United States and Canada, JAMA internal medicine, 173, 1379, 10.1001/jamainternmed.2013.6489 Farnier, 2011, Safety review of combination drugs for hyperlipidemia, Expet Opin. Drug Saf., 10, 363, 10.1517/14740338.2011.540237 Kwon, 2011, Niacin attenuates lung inflammation and improves survival during sepsis by downregulating the nuclear factor-κB pathway, Crit. Care Med., 39, 328, 10.1097/CCM.0b013e3181feeae4 France, 2016, HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom, Atherosclerosis, 255, 128, 10.1016/j.atherosclerosis.2016.10.017 Cuchel, 2014, Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society, Eur. Heart J., 35, 2146, 10.1093/eurheartj/ehu274 Raal, 2017, Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study, The lancet Diabetes & endocrinology, 5, 280, 10.1016/S2213-8587(17)30044-X Gordon, 1997, Recent advances in elucidating the role of the microsomal triglyceride transfer protein in apolipoprotein B lipoprotein assembly, Curr. Opin. Lipidol., 8, 131, 10.1097/00041433-199706000-00002 Blom, 2017, Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in patients with homozygous familial hypercholesterolemia, Circulation, 136, 332, 10.1161/CIRCULATIONAHA.117.028208 Cuchel, 2013, Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study, Lancet, 381, 40, 10.1016/S0140-6736(12)61731-0 Underberg, 2018, LONG-TERM safety and efficacy OF lomitapide IN patients with homozygous familial hypercholesterolemia: three-year data from the lomitapide observational worldwide evaluation registry (lower), J. Am. Coll. Cardiol., 71, A168, 10.1016/S0735-1097(18)30709-5 Goulooze, 2015, Lomitapide. British journal of clinical pharmacology, 80, 179, 10.1111/bcp.12612 Moulin, 2018, Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an "FCS score, Atherosclerosis, 275, 265, 10.1016/j.atherosclerosis.2018.06.814 Paik, 2019, Volanesorsen: first global approval, Drugs, 79, 1349, 10.1007/s40265-019-01168-z Witztum, 2019, Volanesorsen and triglyceride levels in familial chylomicronemia syndrome, N. Engl. J. Med., 381, 531, 10.1056/NEJMoa1715944 Lippi, 2020, Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis, Clin. Chim. Acta, 506, 145, 10.1016/j.cca.2020.03.022 Yang, 2020, Thrombocytopenia and its association with mortality in patients with COVID-19, J. Thromb. Haemostasis, 18, 1469, 10.1111/jth.14848 Liu, 2020, Association between platelet parameters and mortality in coronavirus disease 2019: retrospective cohort study, Platelets, 1, 10.1080/09537104.2020.1847267 Xu, 2020, Mechanism of thrombocytopenia in COVID-19 patients, Ann. Hematol., 99, 1205, 10.1007/s00277-020-04019-0 Durrington, 2007 Hirota, 2015, Drug–drug interactions that interfere with statin metabolism, Expet Opin. Drug Metabol. Toxicol., 11, 1435, 10.1517/17425255.2015.1056149 Miller, 1998, Clinical pharmacokinetics of fibric acid derivatives (fibrates), Clin. Pharmacokinet., 34, 155, 10.2165/00003088-199834020-00003 European Medicines Agency, 2020 Pareek, 2015, Efficacy and safety of fixed dose combination of atorvastatin and hydroxychloroquine: a randomized, double-blind comparison with atorvastatin alone among Indian patients with dyslipidemia, Curr. Med. Res. Opin., 31, 2105, 10.1185/03007995.2015.1087989 Driggin, 2020, Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic, J. Am. Coll. Cardiol., 75, 2352, 10.1016/j.jacc.2020.03.031 Zhu, 2013, Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: a systematic review and meta-analysis, Antivir. Res., 98, 373, 10.1016/j.antiviral.2013.04.009 Chojnacki, 2017, The effects of melatonin on elevated liver enzymes during statin treatment, BioMed Res. Int., 2017, 3204504, 10.1155/2017/3204504 Strandell, 2009, Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction, Br. J. Clin. Pharmacol., 68, 427, 10.1111/j.1365-2125.2009.03473.x Abu Mellal, 2019, The clinical significance of statins-macrolides interaction: comprehensive review of in vivo studies, case reports, and population studies, Therapeut. Clin. Risk Manag., 15, 921, 10.2147/TCRM.S214938 Patel, 2013, Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study, Ann. Intern. Med., 158, 869, 10.7326/0003-4819-158-12-201306180-00004 Bakheit, 2014, Azithromycin. Profiles Drug Subst Excip Relat Methodol, 39, 1, 10.1016/B978-0-12-800173-8.00001-5 Castagne, 2019, Cardiovascular safety of tocilizumab: a systematic review and network meta-analysis, PloS One, 14, 10.1371/journal.pone.0220178 Bellosta, 2018, Statin drug interactions and related adverse reactions: an update, Expet Opin. Drug Saf., 17, 25, 10.1080/14740338.2018.1394455 Schmitt, 2011, Disease–drug–drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis, Clin. Pharmacol. Therapeut., 89, 735, 10.1038/clpt.2011.35 Mehra, 2020, Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, Lancet Lozada, 1994, Drug interactions with fibric acids, Pharmacol. Ther., 63, 163, 10.1016/0163-7258(94)90043-4 Gordon, 2016, Lack of an effect of ritonavir alone and lopinavir-ritonavir on the pharmacokinetics of fenofibric acid in healthy volunteers, Pharmacotherapy, 36, 49, 10.1002/phar.1682 Calza, 2002, Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART, Infection, 30, 26, 10.1007/s15010-001-2052-3 Busse, 1999, Gemfibrozil concentrations are significantly decreased in the presence of lopinavir/ritonavir, J. Acquir. Immune Defic. Syndr., 52, 235, 10.1097/QAI.0b013e3181b0610e Penzak, 2002, Management of protease inhibitor-associated hyperlipidemia, Am. J. Cardiovasc. Drugs, 2, 91, 10.2165/00129784-200202020-00003 Rao, 1997, Effect of dexamethasone on ciprofibrate-induced cell proliferation and peroxisome proliferation, Fund. Appl. Toxicol., 35, 78, 10.1006/faat.1996.2264 Periti, 1992, Pharmacokinetic drug interactions of macrolides, Clin. Pharmacokinet., 23, 106, 10.2165/00003088-199223020-00004 Pappa, 2019, Emerging fixed-dose combination treatments for hyperlipidemia, J. Cardiovasc. Pharmacol. Therapeut., 24, 315, 10.1177/1074248419838506 Arita, 1999, Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity, Biochem. Biophys. Res. Commun., 257, 79, 10.1006/bbrc.1999.0255 Proudman, 2015, Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use, Ann. Rheum. Dis., 74, 89, 10.1136/annrheumdis-2013-204145 Bednasz, 2016, Lipid-lowering therapy in HIV-infected patients: relationship with antiretroviral agents and impact of substance-related disorders, Curr. Vasc. Pharmacol., 14, 280, 10.2174/1570161114666160106151652 Popa, 2007, Impact of obesity and omega-3 polyunsaturated fatty acids on fibrogenesis and responsiveness to antiviral therapy in chronic hepatitis C, Rom. J. Intern. Med., 45, 165 Morsy, 2016, Can eicosapentaenoic acid maintain the original ribavirin dose or affect the response during the treatment course of chronic hepatitis C virus (HCV) patients?, Turk. J. Gastroenterol., 27, 55, 10.5152/tjg.2015.150280 Suzuki, 2012, Prophylaxis for ribavirin-related anemia using eicosapentaenoic acid in chronic hepatitis C patients, Pediatr. Int., 54, 528, 10.1111/j.1442-200X.2012.03603.x Su, 2014, Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: results from a randomized, controlled trial, Biol. Psychiatr., 76, 559, 10.1016/j.biopsych.2014.01.008 Chang, 2017, Polyunsaturated fatty acids levels and initial presentation of somatic symptoms induced by interferon-alpha therapy in patients with chronic hepatitis C viral infection, Nutr. Neurosci., 20, 291, 10.1080/1028415X.2015.1123378 Hanssens, 2016, The clinical benefits of long-term supplementation with omega-3 fatty acids in cystic fibrosis patients - a pilot study, Prostaglandins Leukot. Essent. Fatty Acids, 108, 45, 10.1016/j.plefa.2016.03.014